Working... Menu

The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00690261
Recruitment Status : Unknown
Verified May 2008 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : June 4, 2008
Last Update Posted : June 4, 2008
National Science Council, Taiwan
Information provided by:
National Taiwan University Hospital

Brief Summary:
The purpose of this study is to evaluate the correlation between M1/M2 phenotype of tumor associated macrophage (TAM) in lung cancer patients and clinical outcome.

Condition or disease
Tumor Lung Cancer

Detailed Description:

Inflammatory response in the tumor micro-environment may facilitate the metastatic process (1). Macrophages are pivotal members of the inflammatory cells and the innate immune system within the tumor stroma. Tumor-associated macrophages can release growth factors, cytokines and inflammatory mediators that may facilitate cancer cell invasion, migration, angiogenesis, tumor progression or metastasis (1-5). A lot of studies showed TAM encounter factors that most frequently polarize them toward M2 type macrophage (1,4-5). It is interesting that in vitro studies macrophages have the potential to kill tumor by appropriate stimulation but these macrophage belonged to M1 and were not present in most tumor tissue (6). Some drugs target to suppress TAM have the promising results in animal models (7-9). Switching the TAM phenotype from M2 to M1 may promote anti-tumor activity (10). In this study we will correlate TAM M1/M2 ratio and patients' prognosis, the gene expression pattern of TAM.


  1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-867.
  2. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001;70(4):478-490.
  3. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy. J. Exp. Med. 2001;193(6):727-740.
  4. Mantovani A. Cancer Inflammation by remote control. Nature 2005;435(7043):752-753.
  5. Pollard JW. Tumor-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer 2004;4(1):71-78.
  6. Sica A, Schippa T, Mantovani A, Allavena P. Tumor-associated macrophage are distinct M2 polarized population promoting tumor progression: potential targets of anti-tumor therapy. Eur J of Cancer 2006;42:717-27
  7. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23:1867-74.
  8. Wahl L, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst 1998;90:1583-4.
  9. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-33.
  10. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437-46.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction
Study Start Date : September 2007
Estimated Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

lung cancer
patients diagnosed of lung cancer with malignant pleural effusions

Primary Outcome Measures :
  1. outcome (treatment response and mortality) [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. clinical presentation [ Time Frame: at enrollement ]

Biospecimen Retention:   Samples Without DNA
Pleural effusions and lung cancer tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients diagnosed of lung cancer with malignant pleural effusions

Inclusion Criteria:

  • lung cancer with malignant pleural effusions

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00690261

Layout table for location contacts
Contact: Chao-Chi Ho, Ph.D. 886-2-2356-2905
Contact: Ang Yuan, Ph.D.

Layout table for location information
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Chao-Chi Ho    886-2-2356-2905   
Sponsors and Collaborators
National Taiwan University Hospital
National Science Council, Taiwan
Layout table for investigator information
Principal Investigator: Chao-Chi Ho Department of Internal Medicine and Emergency Medicine, National Taiwan University Hospital

Layout table for additonal information
Responsible Party: Chao-Chi Ho, National Taiwan University Hospital Identifier: NCT00690261     History of Changes
Other Study ID Numbers: 200709004R
First Posted: June 4, 2008    Key Record Dates
Last Update Posted: June 4, 2008
Last Verified: May 2008

Keywords provided by National Taiwan University Hospital:
tumor associated macrophage
lung cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases